Filing search / 2seventy bio, Inc. / "Engagement"

8-K

EX-99.2

TSVT 2seventy bio, Inc.

19 May 23

Regulation FD Disclosure

6:07am

, engagement of antigen and elicitation of CD33 expressing leukemic cell cytotoxicity. Of the two patients who achieved target rapamycin trough levels

PRE 14A

pih4ps

18 Apr 23

Preliminary proxy

5:21pm

8-K

EX-99.1

nxyydy

10 Aug 22

Join the Patient Mission Company Presentation August 2022

12:13pm

424B3

rov x90fiwk834g

6 May 22

Prospectus supplement

4:18pm

S-1

gw651b7h

28 Apr 22

IPO registration

5:03pm

DEF 14A

39usmdxjf8flgvlha8

26 Apr 22

Definitive proxy

4:11pm

10-K

4pctp4hkpd09f0

22 Mar 22

Annual report

7:09am

10-K

EX-10.12

vn6r282ridmzf 623a

22 Mar 22

Annual report

7:09am

10-K

EX-10.13

1atdj nquhavaomty

22 Mar 22

Annual report

7:09am

8-K

EX-99.1

bprhm3m221w

4 Nov 21

Entry into a Material Definitive Agreement

7:24am

10-12B/A

EX-99.1

5huto1

8 Oct 21

Registration of securities (amended)

4:43pm

10-12B/A

EX-10.22

7wj q0apo

8 Oct 21

Registration of securities (amended)

4:43pm

10-12B

EX-10.6

t2yk k0tpjg

9 Sep 21

Registration of securities

4:31pm

10-12B

EX-99.1

vht99 hsk9km5qb

9 Sep 21

Registration of securities

4:31pm

10-12B

EX-10.5

ix5wf9r

9 Sep 21

Registration of securities

4:31pm